JPWO2020163817A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020163817A5
JPWO2020163817A5 JP2021569259A JP2021569259A JPWO2020163817A5 JP WO2020163817 A5 JPWO2020163817 A5 JP WO2020163817A5 JP 2021569259 A JP2021569259 A JP 2021569259A JP 2021569259 A JP2021569259 A JP 2021569259A JP WO2020163817 A5 JPWO2020163817 A5 JP WO2020163817A5
Authority
JP
Japan
Prior art keywords
seq
occupied
antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021569259A
Other languages
English (en)
Japanese (ja)
Other versions
JP7681316B2 (ja
JP2022520672A5 (https=
JP2022520672A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017357 external-priority patent/WO2020163817A1/en
Publication of JP2022520672A publication Critical patent/JP2022520672A/ja
Publication of JPWO2020163817A5 publication Critical patent/JPWO2020163817A5/ja
Publication of JP2022520672A5 publication Critical patent/JP2022520672A5/ja
Priority to JP2024209068A priority Critical patent/JP7843068B2/ja
Application granted granted Critical
Publication of JP7681316B2 publication Critical patent/JP7681316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569259A 2019-02-08 2020-02-07 タウを認識する抗体 Active JP7681316B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024209068A JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962803334P 2019-02-08 2019-02-08
US62/803,334 2019-02-08
US201962813124P 2019-03-03 2019-03-03
US62/813,124 2019-03-03
US201962855434P 2019-05-31 2019-05-31
US62/855,434 2019-05-31
PCT/US2020/017357 WO2020163817A1 (en) 2019-02-08 2020-02-07 Antibodies recognizing tau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024209068A Division JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Publications (4)

Publication Number Publication Date
JP2022520672A JP2022520672A (ja) 2022-03-31
JPWO2020163817A5 true JPWO2020163817A5 (https=) 2023-02-15
JP2022520672A5 JP2022520672A5 (https=) 2023-02-15
JP7681316B2 JP7681316B2 (ja) 2025-05-22

Family

ID=71947192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569259A Active JP7681316B2 (ja) 2019-02-08 2020-02-07 タウを認識する抗体
JP2024209068A Active JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024209068A Active JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Country Status (14)

Country Link
US (1) US20220275067A1 (https=)
EP (1) EP3921343A4 (https=)
JP (2) JP7681316B2 (https=)
KR (1) KR20210125037A (https=)
CN (2) CN113597431B (https=)
AU (1) AU2020219374A1 (https=)
BR (1) BR112021015501A2 (https=)
CA (1) CA3128392A1 (https=)
CO (1) CO2021011140A2 (https=)
IL (1) IL285444A (https=)
MX (1) MX2021009440A (https=)
PE (1) PE20211709A1 (https=)
SG (1) SG11202106717PA (https=)
WO (1) WO2020163817A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2020163817A1 (en) * 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
AU2022306307A1 (en) * 2021-07-09 2024-02-01 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法
WO2025198916A1 (en) * 2024-03-16 2025-09-25 Abbvie Inc. Anti-tau antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7653100A (en) * 1999-09-09 2001-04-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. A minimal tau peptide for the nucleation of paired helical filaments
US8754034B2 (en) * 2009-02-06 2014-06-17 The Regents Of The University Of California Structure-based design of peptide inhibitors of amyloid fibrillation
NZ598356A (en) * 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
ES2656442T3 (es) 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US9738709B2 (en) * 2011-10-21 2017-08-22 Ohio State Innovation Foundation Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CA2902026C (en) * 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
EP4465050A3 (en) * 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
JP7165995B2 (ja) * 2017-02-21 2022-11-07 アールイーエムディー バイオセラピューティクス,インコーポレイテッド 細胞傷害性tリンパ球抗原-4(ctla-4)に結合する抗体を使用した癌治療
WO2020163817A1 (en) 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau

Similar Documents

Publication Publication Date Title
JPWO2020163817A5 (https=)
JP2025029046A5 (https=)
JP2019525724A5 (https=)
IL262726B1 (en) Antibodies recognizing tau
JP2019122405A5 (https=)
JP2023134618A5 (https=)
JP2020528768A5 (https=)
JP2014509861A5 (https=)
JP2018510617A5 (https=)
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2012530496A5 (https=)
JP2017526370A5 (https=)
JP2024056687A5 (https=)
JP2020536532A5 (https=)
JP6633520B2 (ja) プロアポトーシス活性を有するヒトigg1由来抗体
JP2016505546A5 (https=)
JP2012524071A5 (https=)
JP2016539176A5 (https=)
JP2016503067A5 (https=)
JP2018509889A5 (https=)
JP2024086870A5 (https=)
RU2008140947A (ru) Антитела к egfl7 и способы их применения
JP2022535151A (ja) ヒト化抗il17a抗体及びその使用
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2021525059A5 (https=)